BioCardia, Inc. (BCDA): Free Cash Flow
-$7.44M
Year ended 2025-12-31
-$7.57M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$7.44M | n/m | 2026-03-24, From 2025-01-01 |
| 2024-12-31 | -$7.89M | n/c | 2026-03-24, From 2024-01-01 |
| 2023-12-31 | -$9.99M | n/m | 2025-03-26, From 2023-01-01 |
| 2022-12-31 | -$10.63M | n/m | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | -$10.48M | n/m | 2023-03-29, From 2021-01-01 |
| 2020-12-31 | -$12.39M | n/m | 2022-03-29, From 2020-01-01 |
| 2019-12-31 | -$9.59M | n/m | 2021-03-30, From 2019-01-01 |
| 2018-12-31 | -$11.13M | n/m | 2020-04-09, From 2018-01-01 |
| 2017-12-31 | -$8.81M | n/a | 2020-04-09, From 2017-01-01 |
| No annual figure between 2015-12-31 and 2017-12-31. | |||
| 2015-12-31 | -$7.15M | n/a | 2018-03-16, From 2015-01-01 |
| No annual figure between 2012-12-31 and 2015-12-31. | |||
| 2012-12-31 | -$310.0K | n/m | 2014-03-24, From 2012-01-01 |
| 2011-12-31 | -$3.22M | n/m | 2013-03-22, From 2011-01-01 |
| 2010-12-31 | -$5.35M | n/a | 2012-03-29, From 2010-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | 2025-12-31 | -$7.44M | n/m |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $7.57M | n/m |
| Amgen Inc (AMGN) | 2025-12-31 | $8.10B | -22.1% |
| Repligen Corp (RGEN) | 2025-12-31 | $93.90M | -37.3% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | -$5.04M | n/m |
| Bio-Techne Corp (TECH) | 2026-06-30 | $263.22M | +2.6% |
| Biogen Inc. (BIIB) | 2025-12-31 | $2.05B | -24.7% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | -$19.44M | n/m |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $9.46B | -8.2% |
Compare BCDA, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗